Technical Analysis for CHRS - Coherus BioSciences, Inc.

Grade Last Price % Change Price Change
grade C 14.71 -0.20% -0.03
CHRS closed down 0.2 percent on Thursday, April 18, 2019, on 66 percent of normal volume. It was able to find support at its 50 day moving average. It was able to bounce off of its 200 day moving average, an important long-term support line.

Earnings due: May 9

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical CHRS trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
20 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
Doji - Bullish? Reversal 0.00%
Calm After Storm Range Contraction -2.52%
Hammer Candlestick Bullish -1.08%
180 Bullish Setup Bullish Swing Setup -1.08%
Calm After Storm Range Contraction -1.08%
Calm After Storm Range Contraction -0.47%
Inside Day Range Contraction -0.47%

Older signals for CHRS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Medicine Biotechnology Biopharmaceutical Immunology Chemotherapy Breast Cancer Psoriasis Rheumatoid Arthritis Immunosuppressants Biosimilar Recombinant Proteins Treatment Of Breast Cancer Etanercept
Is CHRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.66
52 Week Low 8.32
Average Volume 775,766
200-Day Moving Average 14.2361
50-Day Moving Average 14.3684
20-Day Moving Average 14.295
10-Day Moving Average 14.85
Average True Range 0.8522
ADX 23.65
+DI 30.2139
-DI 19.032
Chandelier Exit (Long, 3 ATRs ) 14.9534
Chandelier Exit (Short, 3 ATRs ) 15.5066
Upper Bollinger Band 15.5931
Lower Bollinger Band 12.9969
Percent B (%b) 0.66
BandWidth 18.161595
MACD Line 0.2019
MACD Signal Line 0.1562
MACD Histogram 0.0457
Fundamentals Value
Market Cap 755.3 Million
Num Shares 51.3 Million
EPS -2.60
Price-to-Earnings (P/E) Ratio -5.66
Price-to-Sales 3.37
Price-to-Book 17.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.35
Resistance 3 (R3) 16.34 15.79 16.07
Resistance 2 (R2) 15.79 15.37 15.79 15.98
Resistance 1 (R1) 15.25 15.12 15.52 15.26 15.89
Pivot Point 14.70 14.70 14.84 14.70 14.70
Support 1 (S1) 14.16 14.28 14.43 14.17 13.53
Support 2 (S2) 13.61 14.03 13.61 13.44
Support 3 (S3) 13.07 13.61 13.35
Support 4 (S4) 13.08